Pulmonary tuberculosis
ICD-10 A15.0 · ICD-11 1B10

Treatment of Pulmonary DS-TB with Stable Chronic Liver Disease (CTP Score 7 or Below)

Drug-susceptible pulmonary tuberculosis (DS-TB) in a patient with stable chronic liver disease—Child-Turcotte-Pugh (CTP) score of 7 or below—requires careful drug selection to avoid compounding hepatic injury while still achieving effective treatment.

Clinical Situation

The patient has confirmed pulmonary DS-TB alongside stable chronic liver disease (CTP ≤7). Because the standard first-line regimen includes drugs with varying degrees of hepatotoxicity, the coexisting liver condition calls for a modified approach. Hepatic tolerance must be actively monitored throughout the course of treatment.

Treatment Approach

Management centres on a liver-sparing drug combination that omits the most hepatotoxic agent in the standard regimen, with the remaining drugs structured into an intensive phase and a continuation phase adapted to the patient's hepatic status. The complete regimen, phase structure, and monitoring parameters are detailed in the full protocol.

Full regimen and monitoring guidance available in the structured protocol below.

Treatment Goals

The primary markers of successful treatment are conversion of the sputum culture to negative, and aminotransferases (ALT and AST) remaining below five times the upper limit of normal throughout therapy.

Instant Access to Structured Evidence-Based Regimens

References

  1. In people with DS-TB with stable CLD (CTP ≤7), a treatment regimen that includes isoniazid, rifampicin and ethambutol is likely to be tolerated, with the exclusion of pyrazinamide (which is the most hepatotoxic drug in the 6-month regimen).
  2. Some experts suggest that, in this situation, the isoniazid and rifampicin continuation phase be prolonged to 7 months, after a 2-month intensive phase with the three drugs.
  3. For pulmonary DS-TB, the most important evidence of improvement is conversion of the sputum culture to negative.
View source ↗